- Home
- AHG vs DAWN Comparison
AHG vs DAWN Comparison
Compare AHG & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | DAWN |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AHG | DAWN |
|---|---|---|
| Price | $1.35 | $21.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.11 |
| AVG Volume (30 Days) | 2.7K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | N/A | $53.52 |
| Revenue Next Year | N/A | $27.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $0.83 | $5.64 |
| 52 Week High | $2.10 | $13.20 |
Technical Indicators
Market Signals| Indicator | AHG | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 82.69 |
| Support Level | $1.24 | $6.40 |
| Resistance Level | $1.67 | N/A |
| Average True Range (ATR) | 0.11 | 0.77 |
| MACD | -0.00 | 0.65 |
| Stochastic Oscillator | 37.04 | 99.73 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.